MX2022011291A - Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. - Google Patents

Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.

Info

Publication number
MX2022011291A
MX2022011291A MX2022011291A MX2022011291A MX2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A
Authority
MX
Mexico
Prior art keywords
gram
treatment
new
bacterial infections
negative bacterial
Prior art date
Application number
MX2022011291A
Other languages
English (en)
Inventor
Martínez Roberto Díez
Areizaga María Morales
Original Assignee
Telum Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telum Therapeutics S L filed Critical Telum Therapeutics S L
Publication of MX2022011291A publication Critical patent/MX2022011291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describe una nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. La presente invención se refiere a una nueva lisina recombinante y su uso como agente antimicrobiano en nuevos enfoques de tratamiento para eliminar bacterias gramnegativas resistentes a antibióticos y minimizar la aparición de nuevas resistencias. Se trata además de polinucleótidos que codifican la lisina recombinante de la invención, vectores y células hospederas que comprenden los mismos, así como métodos, usos médicos, composiciones y kits relacionados.
MX2022011291A 2020-03-11 2021-03-11 Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. MX2022011291A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382177 2020-03-11
EP20382254 2020-03-31
PCT/EP2021/056264 WO2021180892A1 (en) 2020-03-11 2021-03-11 New recombinant lysin and its use in the treatment of gram-negative bacterial infections

Publications (1)

Publication Number Publication Date
MX2022011291A true MX2022011291A (es) 2022-12-08

Family

ID=74859480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011291A MX2022011291A (es) 2020-03-11 2021-03-11 Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.

Country Status (8)

Country Link
US (1) US20230138922A1 (es)
EP (1) EP4118192A1 (es)
JP (1) JP2023517245A (es)
CN (1) CN115605587A (es)
AU (1) AU2021236351A1 (es)
CA (1) CA3175024A1 (es)
MX (1) MX2022011291A (es)
WO (1) WO2021180892A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN114774391B (zh) * 2022-03-09 2023-03-14 华南农业大学 一种抗大肠杆菌的噬菌体内溶素及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009266982B2 (en) * 2008-07-03 2015-06-25 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
EA037202B1 (ru) 2009-06-26 2021-02-18 Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д Слитые белки для лечения инфекций, вызванных грамотрицательными бактериями
US8846865B2 (en) 2009-08-24 2014-09-30 Lysando Ag Endolysin OBPgpLYS
GB2543453A (en) 2014-06-26 2017-04-19 Univ Rockefeller Acinetobacter lysins
MX2018003101A (es) 2015-09-17 2018-12-17 Contrafect Corp Activo de polipeptidos de lisina contra bacterias gram-negativas.
KR20200012844A (ko) * 2017-04-03 2020-02-05 사시나파스 컴퍼니 리미티드 조작된 그람-음성 엔도리신

Also Published As

Publication number Publication date
JP2023517245A (ja) 2023-04-24
AU2021236351A1 (en) 2022-10-06
CN115605587A (zh) 2023-01-13
CA3175024A1 (en) 2021-09-16
WO2021180892A1 (en) 2021-09-16
EP4118192A1 (en) 2023-01-18
US20230138922A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
MX2022011291A (es) Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.
Chessa et al. An overview of Staphylococcus epidermidis and Staphylococcus aureus with a focus on developing countries
PH12019500360A1 (en) Antibiotic compounds
SA521430976B1 (ar) مضادات حيوية كبيرة الحلقة واسعة المدى
EP2046287A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING INFECTIONS
JP2018509415A5 (es)
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
MX2018006190A (es) Antibioticos de amplio espectro macrociclico.
TW200716162A (en) Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria
MX2018006199A (es) Antibioticos de amplio espectro macrociclico.
DE502005010850D1 (de) Antibakterielle amid-makrozyklen iv
MX2007009059A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos.
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
TW200510541A (en) Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
WO2020014501A8 (en) Compositions and methods for the treatment of bacterial infections
EP4223304A3 (en) Novel antimicrobial and anti-cancer therapy
WO2005021575A3 (en) Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties
WO2018140707A8 (en) Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
MX2023015156A (es) Peptidos antimicrobianos modificados.
GEP20247616B (en) Compounds and methods of use thereof as antibacterial agents
WO2021081110A3 (en) Peptides and use thereof
MX2022015155A (es) Formulaciones y metodos para tratar la diarrea.
IL299751A (en) Preparations and methods for disinfection, treatment and prevention of bacterial infections
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
MX2023012943A (es) Compuesto antibacteriano.